The study concluded that the administration of CP consisting of the SARS-CoV-2-specific neutralizing antibodies in critically ill patients might have improved their clinical symptoms, and suggested that CP infusion could be a potential therapeutic strategy against COVID-19 [53], though the observations and results obtained from these studies need to be analysed and evaluated in further clinical trials. The gene discussed is CP; the disease is COVID-19.